wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38128723-1B04FEC0-4903-4C4A-8B75-6E8489C120F5
Q38128723-1B04FEC0-4903-4C4A-8B75-6E8489C120F5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38128723-1B04FEC0-4903-4C4A-8B75-6E8489C120F5
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
P2860
Q38128723-1B04FEC0-4903-4C4A-8B75-6E8489C120F5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38128723-1B04FEC0-4903-4C4A-8B75-6E8489C120F5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
76e671189a8103494b0572666a849a6d6439a6bc
P2860
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.